IP Library Patent Application 11820600
Patent Application
App. No. 11/820,600

Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/820,600
Abstract

Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.

Claims (8)

1 . A method to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a tetrahydro-isoalpha acid.

2 . The method of claim 1 , wherein the tetrahydro-isoalpha acid is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

3 . The method of claim 1 , wherein the protein kinase modulated is selected from the group consisting of Abl(T3151), Aurora-A, Bmx, BTK, CaMKI, CaMKIδ, CDK2/cyclinA, CDK3/cyclinE, CDK9/cyclin T1, CK1(y), CK1γ1, CK1γ2, CK1γ3, CK1δ, cSRC, DAPK1, DAPK2, DRAK1, EphA2, EphA8, Fer, FGFR2, FGFR3, Fgr, Flt4, JNK3, PI3K, Pim-1, Pim-2, PKA, PKA(b), PKBβ, PKBα, PKBγ, PRAK, PrKX, Ron, Rsk1, Rsk2, SGK2, Syk, Tie2, TrkA, and TrkB.

4 . The method of claim 1 , wherein the cancer responsive to kinase modulation is selected from the group consisting of bladder, breast, cervical, colon, lung, lymphoma, melanoma, prostate, thyroid, and uterine cancer.

5 . A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a tetrahydro-isoalpha acid; wherein said therapeutically effective amount modulates a cancer associated protein kinase.

6 . The composition of claim 5 , wherein the tetrahydro-isoalpha acid is selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-adhumulone.

7 . The composition of claim 5 , wherein the composition further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

8 . The composition of claim 5 , wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2007
From: TRIPP, MATTHEW L.; BABISH, JOHN G.; BLAND, JEFFREY S.; KONDA, VEERA; HALL, AMY J.; PACIORETTY, LINDA M.; DESAI, ANU
To: METAPROTEOMICS, LLC
Reel/Frame 019926/0601 →